Equities analysts expect Egalet Corp (NASDAQ:EGLT) to post ($0.38) earnings per share for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Egalet’s earnings, with the lowest EPS estimate coming in at ($0.39) and the highest estimate coming in at ($0.37). Egalet posted earnings of ($0.87) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 56.3%. The business is expected to announce its next quarterly earnings results on Thursday, March 8th.

According to Zacks, analysts expect that Egalet will report full-year earnings of ($2.81) per share for the current year, with EPS estimates ranging from ($2.92) to ($2.50). For the next year, analysts expect that the firm will post earnings of ($1.12) per share, with EPS estimates ranging from ($1.63) to ($0.70). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side analysts that that provide coverage for Egalet.

Egalet (NASDAQ:EGLT) last released its quarterly earnings results on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.46) EPS for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.01.

Several equities research analysts have issued reports on EGLT shares. Gabelli cut shares of Egalet from a “buy” rating to a “hold” rating in a research report on Thursday, November 9th. Cantor Fitzgerald set a $7.00 price objective on shares of Egalet and gave the company a “buy” rating in a research report on Thursday, November 16th. Finally, Stifel Nicolaus cut shares of Egalet from a “buy” rating to a “hold” rating and set a $1.50 price objective for the company. in a research report on Wednesday, January 3rd. One analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $6.20.

A number of institutional investors have recently added to or reduced their stakes in the business. HighTower Advisors LLC boosted its position in Egalet by 0.9% in the 2nd quarter. HighTower Advisors LLC now owns 268,644 shares of the specialty pharmaceutical company’s stock valued at $636,000 after buying an additional 2,408 shares during the period. Virtu KCG Holdings LLC lifted its position in shares of Egalet by 87.0% in the 2nd quarter. Virtu KCG Holdings LLC now owns 79,877 shares of the specialty pharmaceutical company’s stock worth $189,000 after purchasing an additional 37,155 shares during the period. Goldman Sachs Group Inc. lifted its position in shares of Egalet by 515.7% in the 2nd quarter. Goldman Sachs Group Inc. now owns 123,454 shares of the specialty pharmaceutical company’s stock worth $293,000 after purchasing an additional 103,402 shares during the period. NJ State Employees Deferred Compensation Plan purchased a new stake in shares of Egalet in the 3rd quarter worth approximately $435,000. Finally, GMT Capital Corp purchased a new stake in shares of Egalet in the 2nd quarter worth approximately $1,281,000. 50.63% of the stock is owned by institutional investors.

Egalet (NASDAQ EGLT) traded down $0.03 during trading on Tuesday, reaching $1.01. 977,500 shares of the company’s stock traded hands, compared to its average volume of 2,260,000. The stock has a market cap of $43.46, a PE ratio of -0.30 and a beta of 0.44. The company has a debt-to-equity ratio of -3.43, a quick ratio of 2.68 and a current ratio of 2.73. Egalet has a 12 month low of $0.80 and a 12 month high of $6.10.

WARNING: This article was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this article on another site, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The legal version of this article can be read at https://www.americanbankingnews.com/2018/01/16/brokerages-expect-egalet-corp-eglt-will-announce-earnings-of-0-38-per-share.html.

Egalet Company Profile

Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company’s products include OXAYDO and SPRIX Nasal Spray. The Company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology.

Get a free copy of the Zacks research report on Egalet (EGLT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Egalet (NASDAQ:EGLT)

Receive News & Ratings for Egalet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Egalet and related companies with MarketBeat.com's FREE daily email newsletter.